---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-000355"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2026-02-09T23:59:59+00:00"
generated_at: "2026-05-16T03:53:55.114900+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entera Bio appoints former Pfizer exec Geno J. Germano as Chairman, replacing Gerald Lieberman

## Summary
- Geno Germano appointed Class III director and Chairman of the Board effective February 4, 2026.
- Gerald Lieberman resigned as Chairman and Director effective Feb 4, 2026, no disagreement.
- Germano led Pfizer's $14B Global Innovative Pharma business as Group President until 2016.
- Entera plans Phase 3 registrational study for EB613 (osteoporosis) and first-in-human for Long-Acting Oral PTH (hypoparathyroidism) in 2026.

## SEC filing metadata
- accession: 0001178913-26-000355
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2026-02-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891326000355/0001178913-26-000355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891326000355/zk2634303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-000355
- JSON: https://secwatch.observer/filing/0001178913-26-000355.json
- Plain text: https://secwatch.observer/filing/0001178913-26-000355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.